| Home > Publications Database > Impact of low-value medications on quality of life, hospitalization and costs - A longitudinal analysis of patients living with dementia. |
| Journal Article | DZNE-2023-00670 |
; ; ; ; ; ; ; ;
2023
Wiley
Hoboken, NJ
This record in other databases:
Please use a persistent id in citations: doi:10.1002/alz.13012
Abstract: This study aimed to analyze the impact of low-value medications (Lvm), that is, medications unlikely to benefit patients but to cause harm, on patient-centered outcomes over 24 months.This longitudinal analysis was based on baseline, 12 and 24 months follow-up data of 352 patients with dementia. The impact of Lvm on health-related quality of life (HRQoL), hospitalizations, and health care costs were assessed using multiple panel-specific regression models.Over 24 months, 182 patients (52%) received Lvm at least once and 56 (16%) continuously. Lvm significantly increased the risk of hospitalization by 49% (odds ratio, confidence interval [CI] 95% 1.06-2.09; p = 0.022), increased health care costs by €6810 (CI 95% -707€-14,27€; p = 0.076), and reduced patients' HRQoL (b = -1.55; CI 95% -2.76 to -0.35; p = 0.011).More than every second patient received Lvm, negatively impacting patient-reported HRQoL, hospitalizations, and costs. Innovative approaches are needed to encourage prescribers to avoid and replace Lvm in dementia care.Over 24 months, more than every second patient received low-value medications (Lvm). Lvm negatively impact physical, psychological, and financial outcomes. Appropriate measures are needed to change prescription behaviors.
Keyword(s): Humans (MeSH) ; Quality of Life (MeSH) ; Health Care Costs (MeSH) ; Hospitalization (MeSH) ; Dementia: drug therapy (MeSH) ; Alzheimer's disease ; dementia ; health care costs ; health care resources ; health-related quality of life ; hospitalization ; low-value care